Skip to main content

Aptiv, Cancer Genetics Ink Partnership Directed at Cancer Clinical Trials

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Aptiv Solutions today announced a partnership with Cancer Genetics for products and services directed at oncology clinical trials.

The two firms did not specify what products or services will result from the deal, but Aptiv said in a statement that they will provide "biopharmaceutical firms with a better understanding of modes of action of a variety of therapeutics and the role of biomarkers in the oncology drug development process."

"The collaboration will provide customers with the products and services necessary to bring oncology therapeutics to their patients faster and at a reduced cost," the Great Falls, Va.-based firm added.

Financial and other terms of the deal were not disclosed.

Aptiv is a biopharmaceutical and medical device development services organization. Among the services it provides are adaptive trial design, early phase product strategy, regulatory services, pharmacovigilance, "and the operational support of a global clinical research organization," it said.

CGI, based in Rutherford, NJ, provides expertise in disease-specific biomarkers, proprietary molecular testing, and oncology lab services to companies in the early stages of clinical trials.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.